Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGE-3 Vaccine + AS02B vs AS15 in Advanced Melanoma
NCT00086866Phase 2Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2004
- Primary completion
- Jan 2007
- Modality
- Vaccines & Immunotherapeutics, Liposomes, Peptides
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of astuprotimut-R, AS02B and AS15 in melanoma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Objective Response Rate, Activity of Adjuvant (Antigenicity of MAGE-3) and 1 more. Status: unknown.
02
Drugs
astuprotimut-RAS02BAS15
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00086866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086866.